View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAyala Pharmaceuticals 배당 및 자사주 매입배당 기준 점검 0/6Ayala Pharmaceuticals 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 09OS Therapies Incorporated (NYSEAM:OSTX) completed the acquisition of Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS).OS Therapies Incorporated (NYSEAM:OSTX) agreed to acquire Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS) for $8 million on January 29, 2025. A cash consideration of $0.5 million will be paid by OS Therapies Incorporated. Under the terms of the agreement, OS Therapies has agreed to pay $0.5 million in cash and issue $7.5 million worth of OS Therapies’ common shares to Ayala. OS Therapies previously completed a $7.1 million financing, priced at $4.00 per share primarily with existing shareholders, that provides the Company with sufficient cash runway into 2026 inclusive of payments to Ayala. As part of the financing agreement, OS Therapies agreed to appoint Karim Galzahr to the Company’s Board of Directors. The transaction is expected to close 60 days from execution of the agreement, subject to customary closing conditions. OS Therapies Incorporated (NYSEAM:OSTX) completed the acquisition of Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS) on April 9, 2025.공시 • May 10Ayala Pharmaceuticals Files Form 15Ayala Pharmaceuticals, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.001 per share.공시 • Apr 04+ 1 more updateAndres Guttierez, Chief Medical Officer and Executive Vice President, Departs from Ayala Pharmaceuticals, IncOn March 25, 2024, upon the previously announced consummation of the transactions contemplated by that certain Asset Purchase Agreement (the “Asset Purchase Agreement”), dated as of February 5, 2024, between Ayala Pharmaceuticals, Inc. and Immunome, Inc. (“Purchaser”), Andres Guttierez, the Company’s Chief Medical Officer and Executive Vice President, departed the Company.공시 • Apr 02Ayala Pharmaceuticals, Inc. announced delayed annual 10-K filingOn 04/01/2024, Ayala Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Mar 27Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS).Immunome, Inc. (NasdaqCM:IMNM) entered into a definitive asset purchase agreement to acquire Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS) for $94.2 million on February 6, 2024. Based on the terms of the agreement, Immunome will pay Ayala $20 million in cash and $30 million in Immunome common stock (valued at 30-day VWAP as of February 1, 2024) at the closing and will pay up to an additional $37.5 million in development and commercial milestone payments. Completion of the transaction is subject to customary conditions including Ayala obtaining the requisite stockholder approval. A.G.P./Alliance Global Partners is acting as strategic advisor to Ayala Pharmaceuticals, Inc. in connection with the transaction. Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS) on March 26, 2024.공시 • Feb 20Ayala Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 3 Ringside Study Evaluating AL102 in Desmoid TumorsAyala Pharmaceuticals, Inc. announced that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. A total of 156 patients were enrolled. The Phase 3 segment of the RINGSIDE study is a double-blind, multi-center trial enrolling patients with progressive disease, randomized between AL102 1.2 mg dosed once daily or placebo. The primary endpoint is progression-free survival (PFS) with secondary endpoints including objective response rate (ORR), duration of response (DOR), and patient-reported Quality of Life (QOL) measures. RINGSIDE has been designed as a registration study to support a New Drug Application (NDA) in desmoid tumors.공시 • Oct 25Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023Ayala Pharmaceuticals, Inc. announced that new data from the RINGSIDE study evaluating its lead investigational candidate AL102 for the treatment of desmoid tumors (DT) are being presented at the European Society for Molecular Oncology (ESMO) Congress 2023, taking place October 20th to 24th in Madrid, Spain. The data are from Phase 2 (Part A) of the study and from the Open Label Extension (OLE). The results are featured in a poster being presented by Professor Robin Jones, Team Leader in Sarcoma Clinical Trials at The Institute of Cancer Research and Consultant Medical Oncologist at The Royal Marsden, UK. The ongoing Phase 2/3 RINGSIDE clinical trial is a randomized, global multi-center study evaluating AL102 in patients with progressing desmoid tumors. The study consists of two parts: Phase 2 (Part A) is an open-label, dose regimen finding study, and Phase 3 (Part B) is a double blind, placebo-controlled study and Open Label Extension utilizing the 1.2 mg once daily dose regimen selected based on data from Phase 2. Patients in Phase 2 were randomized to one of three dose regimens of AL102 (n=14 each), including 1.2 mg once daily (QD), 4 mg twice a week (BIW) or 2 mg BIW. Patients in the intermittent dosing arms were allowed to rollover to the Open Label Extension to receive 1.2 mg once daily after evaluations were completed in the Phase 2 part. The results presented at ESMO reflect a cut-off date as of July 5, 2023. Efficacy Results: 1.2 mg once daily achieved ORR of 83% per RECIST in the evaluable population as assessed by MRI BICR (Blinded Independent Central Review). ORR per RECIST was 64% in evaluable patients across the 3 dose arms (n=36). Efficacy results continue to demonstrate a dose-response pattern favoring the 1.2 mg once daily arm. First Partial Responses (PRs) observed at 16 weeks and 21 additional PRs and 1 Complete Response across all dose arms. Early and deep volume (-52%) and T2 signal intensity (-58%) reductions within 16 weeks after starting 1.2 mg once daily. Best overall median reductions of 88% and 85% in volume and T2 signal intensity, respectively, in the 1.2 mg once daily arm at 16.6 months of median time on treatment. Reductions in volume and T2 signal intensity were also observed across biweekly dose arms. 29 patients rolled over to the OLE between Oct 2022 and May 2023, with 27 still on study. Three patients from the 4 mg BIW arm achieved PR after rolling over to the OLE where they received 1.2 mg once daily. Safety: AL102 was generally well tolerated with a manageable safety profile across all dose arms. Adverse events (AEs) were consistent with gamma secretase inhibitors’ (GSI) mec anism of action. The most frequent treatment-related AEs with 1.2 mg once daily included diarrhea (92.8%), nausea (57.1%), fatigue (50%), dry skin (50%), alopecia (50%), stomatitis (50%) dermatitis acneiform (42.9%), dry mouth (42.9%), hypophosphatemia (42.9%), rash maculopapular (37.7%) and aspartate aminotransferase increased (28.6%). Regardless of dose regimen, AEs were Grade 1 or Grade 2 in >95% of the cases. There was one Grade 4 unrelated AE and no Grade 5 AEs. There were no treatment-related serious AEs. Ovarian dysfunction was reported in 56% of pre-menopausal women in the 1.2 mg once daily arm and 61% of pre-menopausal women across all dose arms.공시 • Oct 23Ayala Pharmaceuticals, Inc. Announces CFO ChangesEffective as of the Effective Time, Roy Golan, CPA, LLM, will become the Ayala Pharmaceuticals, Inc.'s Chief Financial Officer. Igor Gitelman will cease to serve as the company's Interim Chief Financial Officer at that time. Mr. Golan, 50, is a registered CPA with a broad experience in aspects of Nasdaq, IPOs and M&As. Prior to joining BioSight, Mr. Golan served in several financial management positions in the biotech industry, including as the CFO of Neuroderm, where he had a pivotal role in their successful Nasdaq IPO, two Follow-On Offerings, and Neuroderm's acquisition by Mitsubishi Tanabe Pharmaceutical Corporation for a total of $1.1 billion. Mr. Golan started his career at PriceWaterhouseCoopers (PWC). Mr. Golan is a registered CPA, holds a B.A. in Accounting and Business from the Israeli College of Management School of Business and an LL.M. in Law from Bar Ilan University. Mr. Golan will continue, until such time as new compensation terms are agreed to with the Company, to be compensated in accordance with his existing arrangements at Biosight, including an annual salary of approximately $180,000, and insurance, severance, pension, disability and study fund benefits typical under Israeli employment arrangements.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 ADXS 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: ADXS 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Ayala Pharmaceuticals 배당 수익률 vs 시장ADXS의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (ADXS)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.5%분석가 예측 (ADXS) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ADXS 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ADXS 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ADXS 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: ADXS 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/02/05 04:39종가2026/02/03 00:00수익2023/12/31연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Ayala Pharmaceuticals, Inc.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Ahu DemirLadenburg Thalmann & Company
공시 • Apr 09OS Therapies Incorporated (NYSEAM:OSTX) completed the acquisition of Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS).OS Therapies Incorporated (NYSEAM:OSTX) agreed to acquire Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS) for $8 million on January 29, 2025. A cash consideration of $0.5 million will be paid by OS Therapies Incorporated. Under the terms of the agreement, OS Therapies has agreed to pay $0.5 million in cash and issue $7.5 million worth of OS Therapies’ common shares to Ayala. OS Therapies previously completed a $7.1 million financing, priced at $4.00 per share primarily with existing shareholders, that provides the Company with sufficient cash runway into 2026 inclusive of payments to Ayala. As part of the financing agreement, OS Therapies agreed to appoint Karim Galzahr to the Company’s Board of Directors. The transaction is expected to close 60 days from execution of the agreement, subject to customary closing conditions. OS Therapies Incorporated (NYSEAM:OSTX) completed the acquisition of Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS) on April 9, 2025.
공시 • May 10Ayala Pharmaceuticals Files Form 15Ayala Pharmaceuticals, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.001 per share.
공시 • Apr 04+ 1 more updateAndres Guttierez, Chief Medical Officer and Executive Vice President, Departs from Ayala Pharmaceuticals, IncOn March 25, 2024, upon the previously announced consummation of the transactions contemplated by that certain Asset Purchase Agreement (the “Asset Purchase Agreement”), dated as of February 5, 2024, between Ayala Pharmaceuticals, Inc. and Immunome, Inc. (“Purchaser”), Andres Guttierez, the Company’s Chief Medical Officer and Executive Vice President, departed the Company.
공시 • Apr 02Ayala Pharmaceuticals, Inc. announced delayed annual 10-K filingOn 04/01/2024, Ayala Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Mar 27Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS).Immunome, Inc. (NasdaqCM:IMNM) entered into a definitive asset purchase agreement to acquire Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS) for $94.2 million on February 6, 2024. Based on the terms of the agreement, Immunome will pay Ayala $20 million in cash and $30 million in Immunome common stock (valued at 30-day VWAP as of February 1, 2024) at the closing and will pay up to an additional $37.5 million in development and commercial milestone payments. Completion of the transaction is subject to customary conditions including Ayala obtaining the requisite stockholder approval. A.G.P./Alliance Global Partners is acting as strategic advisor to Ayala Pharmaceuticals, Inc. in connection with the transaction. Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS) on March 26, 2024.
공시 • Feb 20Ayala Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 3 Ringside Study Evaluating AL102 in Desmoid TumorsAyala Pharmaceuticals, Inc. announced that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. A total of 156 patients were enrolled. The Phase 3 segment of the RINGSIDE study is a double-blind, multi-center trial enrolling patients with progressive disease, randomized between AL102 1.2 mg dosed once daily or placebo. The primary endpoint is progression-free survival (PFS) with secondary endpoints including objective response rate (ORR), duration of response (DOR), and patient-reported Quality of Life (QOL) measures. RINGSIDE has been designed as a registration study to support a New Drug Application (NDA) in desmoid tumors.
공시 • Oct 25Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023Ayala Pharmaceuticals, Inc. announced that new data from the RINGSIDE study evaluating its lead investigational candidate AL102 for the treatment of desmoid tumors (DT) are being presented at the European Society for Molecular Oncology (ESMO) Congress 2023, taking place October 20th to 24th in Madrid, Spain. The data are from Phase 2 (Part A) of the study and from the Open Label Extension (OLE). The results are featured in a poster being presented by Professor Robin Jones, Team Leader in Sarcoma Clinical Trials at The Institute of Cancer Research and Consultant Medical Oncologist at The Royal Marsden, UK. The ongoing Phase 2/3 RINGSIDE clinical trial is a randomized, global multi-center study evaluating AL102 in patients with progressing desmoid tumors. The study consists of two parts: Phase 2 (Part A) is an open-label, dose regimen finding study, and Phase 3 (Part B) is a double blind, placebo-controlled study and Open Label Extension utilizing the 1.2 mg once daily dose regimen selected based on data from Phase 2. Patients in Phase 2 were randomized to one of three dose regimens of AL102 (n=14 each), including 1.2 mg once daily (QD), 4 mg twice a week (BIW) or 2 mg BIW. Patients in the intermittent dosing arms were allowed to rollover to the Open Label Extension to receive 1.2 mg once daily after evaluations were completed in the Phase 2 part. The results presented at ESMO reflect a cut-off date as of July 5, 2023. Efficacy Results: 1.2 mg once daily achieved ORR of 83% per RECIST in the evaluable population as assessed by MRI BICR (Blinded Independent Central Review). ORR per RECIST was 64% in evaluable patients across the 3 dose arms (n=36). Efficacy results continue to demonstrate a dose-response pattern favoring the 1.2 mg once daily arm. First Partial Responses (PRs) observed at 16 weeks and 21 additional PRs and 1 Complete Response across all dose arms. Early and deep volume (-52%) and T2 signal intensity (-58%) reductions within 16 weeks after starting 1.2 mg once daily. Best overall median reductions of 88% and 85% in volume and T2 signal intensity, respectively, in the 1.2 mg once daily arm at 16.6 months of median time on treatment. Reductions in volume and T2 signal intensity were also observed across biweekly dose arms. 29 patients rolled over to the OLE between Oct 2022 and May 2023, with 27 still on study. Three patients from the 4 mg BIW arm achieved PR after rolling over to the OLE where they received 1.2 mg once daily. Safety: AL102 was generally well tolerated with a manageable safety profile across all dose arms. Adverse events (AEs) were consistent with gamma secretase inhibitors’ (GSI) mec anism of action. The most frequent treatment-related AEs with 1.2 mg once daily included diarrhea (92.8%), nausea (57.1%), fatigue (50%), dry skin (50%), alopecia (50%), stomatitis (50%) dermatitis acneiform (42.9%), dry mouth (42.9%), hypophosphatemia (42.9%), rash maculopapular (37.7%) and aspartate aminotransferase increased (28.6%). Regardless of dose regimen, AEs were Grade 1 or Grade 2 in >95% of the cases. There was one Grade 4 unrelated AE and no Grade 5 AEs. There were no treatment-related serious AEs. Ovarian dysfunction was reported in 56% of pre-menopausal women in the 1.2 mg once daily arm and 61% of pre-menopausal women across all dose arms.
공시 • Oct 23Ayala Pharmaceuticals, Inc. Announces CFO ChangesEffective as of the Effective Time, Roy Golan, CPA, LLM, will become the Ayala Pharmaceuticals, Inc.'s Chief Financial Officer. Igor Gitelman will cease to serve as the company's Interim Chief Financial Officer at that time. Mr. Golan, 50, is a registered CPA with a broad experience in aspects of Nasdaq, IPOs and M&As. Prior to joining BioSight, Mr. Golan served in several financial management positions in the biotech industry, including as the CFO of Neuroderm, where he had a pivotal role in their successful Nasdaq IPO, two Follow-On Offerings, and Neuroderm's acquisition by Mitsubishi Tanabe Pharmaceutical Corporation for a total of $1.1 billion. Mr. Golan started his career at PriceWaterhouseCoopers (PWC). Mr. Golan is a registered CPA, holds a B.A. in Accounting and Business from the Israeli College of Management School of Business and an LL.M. in Law from Bar Ilan University. Mr. Golan will continue, until such time as new compensation terms are agreed to with the Company, to be compensated in accordance with his existing arrangements at Biosight, including an annual salary of approximately $180,000, and insurance, severance, pension, disability and study fund benefits typical under Israeli employment arrangements.